The MHRA has licensed several GLP-1 agonists for use in the UK, and NICE guidelines (NG28) recommend them for specific patient groups, particularly those with type 2 diabetes who have not achieved adequate control with other medications or who have additional cardiovascular risk factors
Reports of skin irritation and blisters with some patch products add safety concerns to the effectiveness questions
GLP-1s appear to run that cycle in reverse
Several studies have compared non-syndromic obesity and PWS, but there is limited data available on the clinical features associated with specific PWS genotypes
They can be effective, but most people stop taking them within months, and weight often returns when they do
This often occurs when a gallstone blocks the cystic duct, causing bile buildup, pressure, and potential infection